Generic and biosimilar launches don’t happen on a calendar—they happen when exclusivity breaks.
That sounds obvious, until you’re staring at a formulary decision with incomplete data, shifting payer dynamics, and a clock that’s already running. The r…

Pharma’s next move is often hiding in plain sight—before the public “pipeline” ever hits the web.
If you’ve ever watched a company unveil a blockbuster candidate only to realize the market had already priced it in weeks (or months) earlier, you’ve seen…

20 Years on Paper—But What Happens in Real Life? The Hidden Mechanics of U.S. Drug Patent Duration
Most people hear “20-year patent term” and assume the clock starts, runs cleanly, and ends predictably. In the U.S. drug world, that’s rarely how it play…

Pick the right patent—or leave billions on the table.
In pharma, the difference between winning and losing often isn’t science. It’s paperwork—timing, strategy, and the legal architecture that determines whether exclusivity actually holds when it mat…

South America is often treated as one market. It isn’t.
If you’re building a pipeline, underwriting risk, or planning launches, the real story is country-by-country—because patent landscapes don’t travel well across borders. A “strong” patent position …

Most 505(b)(2) strategies fail before the first filing—because teams treat “regulatory pathway” like a checkbox, not a business model.
If you’re a CDMO, specialty lab, or development partner supporting companies pursuing 505(b)(2) follow-on drugs, th…

Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/

Pharma doesn’t always “block” generics with one big wall.
More often, it builds a wall brick by brick—layering exclusivities, tweaking regulatory pathways, and using the fine print of drug law to extend market control long after the original patent clo…

India’s “drug patent clock” is one of the most misunderstood timelines in global pharma.
On paper, patents look like clean, predictable protection: file today, enjoy exclusivity tomorrow, and monetize until the clock runs out. In practice, India’s drug…

The Hatch-Waxman playbook is no longer a back-office exercise—it’s the front line of a $467B race.
If you think Paragraph IV certifications and 180-day exclusivity are “just legal mechanics,” you’re missing the real story: they’re the timing engine beh…